%0 Journal Article
%A Oeckl, Patrick
%A Abu-Rumeileh, Samir
%A Weise, Christopher M
%A Otto, Markus
%T Longitudinal changes of blood β-synuclein in cognitively unimpaired, mild cognitive impairment and sporadic Alzheimer´s disease.
%J Alzheimer's research & therapy
%V 18
%N 1
%@ 1758-9193
%C London
%I BioMed Central
%M DZNE-2026-00237
%P 45
%D 2026
%X β-Synuclein is an emerging synaptic blood biomarker for Alzheimer´s disease (AD) and correlates with cognitive impairment, brain atrophy and amyloid/tau pathology. Longitudinal data from individual patients are missing so far but are important to evaluate how changes of β-synuclein might be used in early diagnosis, prediction, disease progression and treatment monitoring.In this observational study, we investigated serum β-synuclein by immunoprecipitation-mass spectrometry (IP-MS) in 463 participants from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) including clinically diagnosed cognitively unimpaired, mild cognitive impairment (MCI) and AD dementia subjects with ≥ 1 follow-up samples for 235 individuals and clinical follow-up for up to 19 years. CSF AD biomarker levels were available for 194 participants.Participants (40.0
%K Blood biomarker (Other)
%K Longitudinal observation (Other)
%K Mild cognitive impairment (Other)
%K Sporadic Alzheimer´s disease (Other)
%K Synaptic degeneration (Other)
%K β-synuclein (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:41673920
%2 pmc:PMC12930813
%R 10.1186/s13195-026-01973-1
%U https://pub.dzne.de/record/285455